IMI impact on antimicrobial resistance Online event

On 31 May 2024 from 14:00 CET to 15:30 CET, the Innovative Health Initiative is organising an online event IMI Impact on antimicrobial resistance.

The goal of this event is to highlight the impacts that the COMBACTE projects are having in tackling antimicrobial resistance (AMR).

AMR is considered to be one of the top global public health and development threats, and it's estimated to cause more than 35 000 deaths per year in the EU. Despite this, few new antibiotics make it onto the market, meaning that there is an urgent need for innovative antimicrobials to treat resistant infections.

The COMBACTE projects - COMBACTE-NET, COMBACTE-MAGNET and COMBACTE-CARE formed public-private partnerships with the goal of addressing the challenges of clinical development of antibacterial medicines in response to antibiotic resistance. The COMBACTE projects are part of IMI's New Drugs for Bad Bugs programme, which comprises several projects that are finding solutions to the scientific, regulatory, and business challenges that are hampering the development of new antibiotics.

IHI’s senior scientific officer, Nathalie Seigneuret, will moderate the discussion between:

  • Marc Bonten, professor of infection and immunity at UMC Utrecht and chief executive officer of Ecraid
  • Jesús Rodríguez Baño, professor of medicine in infectious diseases at the Hospital Universitario Virgen Macarena, University of Sevilla and Instituto of Biomedicine of Sevilla
  • Halley Rogers, director of clinical research at Pfizer
  • Bruno François, doctor of medicine and COMBACTE-NET academic lead, CHU Limoges
  • Hasan Jafri, chief medical officer and head of clinical development, Aridis Pharmaceuticals

Read the COMBACTE-NET factsheet:

Read the COMBACTE-MAGNET factsheet:

Read the COMBACTE-CARE factsheet: